A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state.
Van Lint S, Van Parys A, Van Den Eeckhout B, Vandamme N, Plaisance S, Verhee A, Catteeuw D, Rogge E, De Geest J, Vanderroost N, Roels J, Saeys Y, Uzé G, Kley N, Cauwels A, Tavernier J.
Van Lint S, et al. Among authors: kley n.
Mol Cancer. 2023 Nov 29;22(1):191. doi: 10.1186/s12943-023-01908-6.
Mol Cancer. 2023.
PMID: 38031106
Free PMC article.